3CLpro PROTACs (Panlong Pharma)

N/A

Report date: 2023/03/02 10:06:17
NME

Base Information

Drug Name3CLpro PROTACs (Panlong Pharma)
Drug Alias NamePLC-01 PROTAC(Panlong Pharma)
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShanxi Panlong Pharmaceutical Group Limited By Share Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanxi Panlong Pharmaceutical Group Limited By Share Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A